Dr. Cheryl Blanchard, Ph.D., has been elected as a Class III director effective April 15, 2026. Dr. Blanchard will serve as chair of the Compensation Committee and as a member of the Audit Committee. The appointment follows the resignation of Christina Rossi, who stepped down from the Board and all committees on April 15, 2026. Dr. Blanchard's compensation includes a $40,000 annual board fee, $12,000 for chairing the Compensation Committee, and $7,500 for Audit Committee service. Initial equity compensation includes a stock option grant for 10,000 shares, vesting annually over three years.